Prostate Cancer Research Uncovers Insights into Radiation Therapy Benefits and Risks

Strategic Insights -

A new study conducted at Orebro University Hospital in Sweden has shed light on the benefits and risks of radiation therapy in prostate cancer treatment. The researchers examined the impact of moderately hypofractionated prostate-only radiotherapy versus whole-pelvis radiation therapy on prognosis, toxicity, and quality of life in patients with high-risk prostate cancer. The study involved 516 patients treated between 2008 and 2021. According to the findings, there were no significant differences in oncological outcomes or quality of life between the two treatment groups. However, patients receiving whole-pelvis radiation therapy experienced a higher risk of acute genitourinary toxicities.

Key Takeaways:

  • The study involved 516 patients with high-risk prostate cancer treated at Orebro University Hospital between 2008 and 2021.
  • Patients were divided into two groups: those receiving moderately hypofractionated prostate-only radiotherapy (PORT) and those receiving whole-pelvis radiation therapy (WPRT).
  • The study found no significant differences in 5-year biochemical failure-free survival (BFFS) rates between the two groups: 77% for PORT and 74% for WPRT.
  • Whole-pelvis radiation therapy was associated with a higher risk of acute grade 2 and 3 genitourinary toxicities.
  • No significant differences were found in metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), or overall survival (OS) between the two groups.
  • The study concluded that while whole-pelvis radiation therapy was associated with a higher risk of acute toxicities, there were no significant differences in oncological outcomes or quality of life between the two treatment groups.

Statistics:

  • 516 patients were included in the study.
  • 227 patients received prostate-only radiotherapy (PORT).
  • 289 patients received whole-pelvis radiation therapy (WPRT).
  • 5-year biochemical failure-free survival (BFFS) rates were 77% for PORT and 74% for WPRT.
  • Adjusted hazard ratio (HR) for BFFS was 1.50 (95% CI = 0.88-2.55) in favor of WPRT.
  • No significant differences were found in metastasis-free survival (MFS), prostate cancer-specific survival (PCSS), or overall survival (OS) between the two groups.

Sources:

  • Kahlmeter Brandell, J., et al. (2024). Moderately hypofractionated prostate-only versus whole-pelvis radiotherapy for high-risk prostate cancer: A retrospective real-world single-center cohort study. Clinical and Translational Radiation Oncology, 48, 100846. doi: 10.1016/j.ctro.2024.100846
  • Clinical and Translational Radiation Oncology. (n.d.). Retrieved from https://www.journals.elsevier.com/clinical-and-translational-radiation-oncology
  • Orebro University Hospital. (n.d.). Retrieved from https://www.orebrouniversityhospital.se/